tirzepatide study outperformed semaglutide weight-loss drug results in real world patients, shows Study: Tirzepatide produces greater weight

As more research emerges, GLP-1 medications may become a powerful adjunct therapy in rheumatologysupporting traditional treatments and improving long-term outcomes

Tirzepatide, a medication initially developed for type 2 diabetes, has shown incredible promise in helping individuals lose weight

After the initial 36 weeks, participants lost 21.1% of their body weight After the following 52 weeks, the tirzepatide group lost another 6.7% of their body weight, while the placebo group regained 14.8% Through the 88-week study, the tirzepatide group lost 26% of their body weight Tirzepatide had a similar safety profile in SURMOUNT-3 and SURMOUNT-4 as its previous trials, most commonly citing mild-moderate gastrointestinal issues

Over-the-counter remedies like vitamin B6 (50100 mg daily) and ginger supplements show modest benefit in clinical practice

Qi, Y., Amiram, M., Gao, W., McCafferty, D